| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 3.9K | 35.5% | 15.2% |
| Total Income | 3.9K | 36.9% | 15.4% |
| Expenditure | 3.2K | 17.2% | 8.9% |
| PBT | 534.00 | 44.8% | 17.0% |
| Net Profit | 403.23 | 33.9% | 15.9% |
| OPM | 17.57% | 1.46pp | 10.19pp |
| NPM | 10.22% | 0.45pp | 0.04pp |
| EPS | 14.29 | 33.9% | 15.9% |
Glenmark Pharmaceuticals Reports Q3 FY26 Results: 15.1% YoY Revenue Growth, 15.9% YoY PAT Growth
30 Jan 2026 · 30 Jan, 8:23 pm
Summary
Glenmark Pharmaceuticals Ltd. has announced its financial results for the third quarter ended December 31, 2025. The company's consolidated revenue was at Rs. 39,006 Mn, registering an overall growth of 15.1% YoY. EBITDA was Rs. 8,697 Mn, registering 44.9% YoY growth, and an EBITDA margin of 22.3%. Profit After Tax (PAT) for the quarter was Rs. 4,032 Mn, registering 15.9% YoY growth, with a PAT margin of 10.3%.
Key Highlights
- 1
India Formulations revenue up by 22.1% YoY at Rs. 12,986 Mn
- 2
North America revenue grew by 24.2% YoY to Rs. 9,706 Mn (Includes out-licensing income for ISB 2001)
- 3
Europe revenue grew by 9.1% YoY to Rs.7,963 Mn
- 4
Emerging Markets revenue up by 8.4% YoY to Rs. 8,119 Mn
- 5
EBITDA of Rs. 8,697 Mn, 44.9% YoY growth, with an EBITDA margin of 22.3%
- 6
Profit After Tax (PAT) of Rs. 4,032 Mn, 15.9% YoY growth with PAT margin of 10.3%
Management Comments
Glenn Saldanha
We delivered strong double-digit revenue growth in the third quarter, reflecting disciplined execution across markets and keeping us on track to deliver our near-term guidance. India continued to outperform in our core therapies. In North America, we advanced our portfolio through new launches, pipeline progression, and the positive regulatory outcome at Monroe. Europe and Emerging markets demonstrated improved momentum, supported by our respiratory franchise and expanding global brands. Our innovative portfolio is shaping up well to become a meaningful growth contributor. RYALTRIS® is scaling across markets, WINLEVI® is gaining traction in the U.K. and has received approval in Europe. Our partnered oncology assets including QiNHAYO™, Trastuzumab Rezetecan and Aumolertinib will strengthen our presence in high-need markets. We are building a more innovation-led Glenmark with a structurally stronger and more sustainable growth trajectory.
Informational and educational content only. Not investment advice.